Circulating Fibrocytes in Non-small Cell Lung Cancer.

• Conditions: NSCLC

• Registration Number: NCT01998425
• Lead Sponsor: Chang Gung Memorial Hospital

Brief Summary

The investigators will collect fibrocytes (CD45+Col-1+) in patients with non-small cell lung cancer (NSCLC). The investigators hypothesize that patients with NSCLC experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in NSCLC patients.

Detailed Description

Fibrocytes have been described in both mice and humans, where they bear a hematopoietic progenitor phenotype (CD45+Col-1+). Fibrocytes have previously been described in murine cancer, implicated as mediators of tumor immune escape. In this study, the investigators will collect fibrocytes including CD45+Col-1+ expression. The cells express indoleamine oxidase, which is primarily responsible for their immunosuppressive properties. The investigators hypothesize that patients with non-small cell lung cancer experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in non-small cell lung cancer patients.

Study Timeline

• Status Verified: 2013-10
• Study Start: 2013-11
• Study First Submitted: 2013-11-13
• Study First Submitted QC: 2013-11-24
• Study First Posted: 2013-11-28
• Last Update Submitted: 2015-07-29
• Last Update Posted: 2015-07-31
• Primary Completion: 2017-02
• Study Completion: 2017-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

Exclusion Criteria

• Combination of other malignancy.
• Age less than 20 years (not include 20 years).
• Pregnancy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
treatment response of participants by RECIST.	18 months	Correlation of circulating fibrocytes and treatment (chemotherapy, surgery, target treatment) response of patients with NSCLC.

Secondary Outcome Measures

Name	Time	Method
Survival of participants.	24 months	Correlation of circulating fibrocytes and survival (progression free survival, disease free survival and overall survival) of patients with NSCLC.

Trial Locations

Locations (2)

Chang Gung Memoral Hospital; 🇨🇳 Taoyuan, Taiwan

Chang Gung Memorial Hospital; 🇨🇳 Linkou, Taiwan